While the observed decrease in both GBA1 and UCGC expression levels during the three-week course of antidepressive therapy, leading toward normalization, was only noted in the subgroup of patients already receiving medication at the time of inclusion, it further underscores the potential involvement of these PD-related sphingolipid enzymes in MDD. Here, GBA1 is linked to major depressive disorder.